| __timestamp | Mesoblast Limited | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 54170000 | 49315000 |
| Thursday, January 1, 2015 | 65378000 | 75043000 |
| Friday, January 1, 2016 | 52263000 | 83749000 |
| Sunday, January 1, 2017 | 35072000 | 122682000 |
| Monday, January 1, 2018 | 27415000 | 207761000 |
| Tuesday, January 1, 2019 | 36983000 | 284812000 |
| Wednesday, January 1, 2020 | 50918000 | 317875000 |
| Friday, January 1, 2021 | 63586000 | 282660000 |
| Saturday, January 1, 2022 | 57967000 | 451421000 |
| Sunday, January 1, 2023 | 53107000 | 481871000 |
| Monday, January 1, 2024 | 23626000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Sarepta Therapeutics, Inc. and Mesoblast Limited offer a fascinating study in contrasts. From 2014 to 2023, Sarepta's SG&A expenses surged by over 870%, peaking in 2023. This reflects their aggressive expansion and investment in R&D. In contrast, Mesoblast's SG&A costs fluctuated, peaking in 2015 and then declining by 64% by 2024, indicating a more conservative approach.
While Sarepta's strategy may suggest robust growth, it also raises questions about sustainability. Mesoblast, with its more stable SG&A trajectory, might appeal to investors seeking steadiness. The absence of 2024 data for Sarepta leaves room for speculation on their future cost management strategies. As these companies navigate the biotech landscape, their SG&A management will be pivotal in shaping their financial narratives.
Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs TG Therapeutics, Inc.
Sarepta Therapeutics, Inc. or MorphoSys AG: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Evotec SE
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Breaking Down SG&A Expenses: Mesoblast Limited vs Galapagos NV